Richard Manch, MD
Hepatology · Glendale, AZNPI 1043289341
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $387,792 of the $534,361 with a category attached, or 72.6%. 30 manufacturers reported payments, led by Gilead at 39.0% of the total.
Across 844 payments — averaging $633.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$209K
- AbbVie$137K
- Intercept Pharmaceuticals, Inc.$50K
- Eisai Inc.$46K
- Madrigal Pharmaceuticals$42K
- Ipsen Biopharmaceuticals, Inc$15K
- plus $36K from 24 others
Across 217 payments — averaging $3131.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Intercept Pharmaceuticals, Inc.$382K
- Bausch Health US, LLC$158K
- E.r. Squibb & Sons, L.L.C.$44K
- Regeneron$30K
- AstraZeneca$18K
- Intercept Pharma Europe Ltd.$14K
- plus $33K from 6 others
What the payments were for
- Consulting fees$80,72815%
- Speaking & faculty fees$387,79273%
- Travel & lodging$42,9608%
- Food & beverage$22,7294%
- Education$540%
- Gifts$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 284 | $208,543 |
| AbbVie | 234 | $136,959 |
| Intercept Pharmaceuticals, Inc. | 66 | $49,652 |
| Eisai Inc. | 64 | $46,086 |
| Madrigal Pharmaceuticals | 55 | $41,651 |
| Ipsen Biopharmaceuticals, Inc | 34 | $15,161 |
| Exelixis Inc. | 19 | $13,508 |
| Dynavax Technologies Corporation | 3 | $7,847 |
| Dova Pharmaceuticals | 6 | $6,557 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 27 | $3,316 |
| GSK | 1 | $2,600 |
| Shionogi Inc | 6 | $869 |
| AstraZeneca(2 entities) | 12 | $352 |
| Novo Nordisk | 4 | $193 |
| Intra-sana Laboratories | 5 | $180 |
| Sirtex Medical Inc | 1 | $163 |
| Orphalan Inc | 5 | $116 |
| Albireo Pharma, Inc. | 1 | $112 |
| Merck | 4 | $97 |
| Sobi, Inc | 1 | $91 |
| Histosonics, Inc. | 1 | $59 |
| Boston Scientific | 2 | $48 |
| Lilly USA, LLC | 1 | $42 |
| Bayer | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| Fujifilm Healthcare Americas Corporation | 1 | $20 |
| Fujifilm Wako Diagnostics U.S.A. Corporation | 1 | $19 |
| Exact Sciences | 1 | $18 |
| Pharmacosmos Therapeutics Inc. | 1 | $17 |
| Eton Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Epclusa$156,274
- Mavyret$111,100
- OCALIVA$48,500
- LENVIMA$45,050
- REZDIFFRA$39,127
- Livdelzi$30,050
- Cabometyx$12,440
- Heplisav-B$7,810
- IQIRVO$7,288
- Creon$6,938
- DOPTELET$6,512
- Bylvay$4,752
- XIFAXAN$2,837
- Mulpleta$750
- SIR-Spheres Microspheres$163
- RESMETIROM$150
- Descovy$103
- Reltone 200 Mg$100
- Reltone 400 Mg$100
How this compares
Too few hepatology providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 92 | $2,222,468 |
| OcalivaObeticholic Acid | 16 | $222,519 |
| MavyretGlecaprevir/Pibrentasvir | 12 | $158,822 |
| XifaxanRifaximin | 32 | $110,569 |
| VemlidyTenofovir Alafenamide | 39 | $63,112 |
| RezdiffraResmetirom | 12 | $47,277 |
| LinzessLinaclotide | 14 | $9,390 |
| Ursodiol | 52 | $9,162 |
| Tacrolimus | 15 | $1,162 |
| ConstuloseLactulose | 11 | $929 |
| Azathioprine | 25 | $840 |
| Lactulose | 24 | $645 |
| Spironolactone | 49 | $474 |
| Furosemide | 53 | $172 |
| Prednisone | 33 | $111 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa, Vemlidy | $208,543 | $2,285,580131 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $49,652 | $222,51916 claims |
| AbbVieMavyret, Linzess | $136,959 | $168,21326 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $3,316 | $110,56932 claims |
| Madrigal PharmaceuticalsRezdiffra | $41,651 | $47,27712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hepatology providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other hepatology in Glendale
- Keith LindorScottsdale$19K
- Jinendra SatiyaYuma$945
- Kathia Jusino SuarezChandler$724
- Alberto RamosPhoenix$551
- Ester LittlePhoenix$340
- David TwitchellPhoenix$298
- Geetha KolliPhoenix$219
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.